These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25575713)

  • 1. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
    Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
    Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
    Dohn LH; Pappot H; Iversen BR; Illemann M; Høyer-Hansen G; Christensen IJ; Thind P; Salling L; von der Maase H; Laerum OD
    PLoS One; 2015; 10(8):e0135824. PubMed ID: 26292086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry.
    Laerum OD; Ovrebo K; Skarstein A; Christensen IJ; Alpízar-Alpízar W; Helgeland L; Danø K; Nielsen BS; Illemann M
    Int J Cancer; 2012 Aug; 131(3):558-69. PubMed ID: 21866548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
    Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
    Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
    Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
    Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
    Casella R; Shariat SF; Monoski MA; Lerner SP
    Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
    Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
    Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
    Vivani C; Magi S; Mazzucchelli R; Bacchiocchi R; Santinelli A; Muzzonigro G; Blasi F; Montironi R; Fazioli F
    Anal Quant Cytol Histol; 2004 Feb; 26(1):15-21. PubMed ID: 15032076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
    Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
    Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.
    Kim SP; Frank I; Cheville JC; Thompson RH; Weight CJ; Thapa P; Boorjian SA
    J Urol; 2012 Aug; 188(2):405-9. PubMed ID: 22704101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.